Molecular Insight Pharmaceuticals, Inc.

Biogen, Incorporated

Biogen Idec Ma Inc.

Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

Molecular Insight Pharmaceuticlas, Inc.

Craig N Zimmerman

John W Babich

Kevin P Maresca

John L Joyal

Genliang Lu

Alfredo C Castro

Steven P Adams

Wen-Cherng Lee

Ko-Chung Lin

Charles E Hammond

Shawn Hillier

Julio Hernan Cuervo

John Marquis

Yu-Sheng Liao

Mary Beth Carter

Jian-cheng Wang

Ronald G Almquist

John Jeffrey Talley

Mark G Currie

Juswinder Singh

Barbara B Chen

G Todd Milne

Brian Cali

Yueh-Tyng Chien

Kevin Sprott

Ara Mermerian

Timothy Claude Barden

James Philip Pearson

Charles Kim

Jane Yang

Wilmin Bartolini

Chris Barone

Regina Lundigran

Jing Jing Yang

Jian-Cheng Wang

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Triazine based radiopharmaceuticals and radioimaging agents

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA. 

Compounds of Formula (Ia) wherein R is a C-Csubstituted or unsubstituted aryl, a C-Csubstituted or unsubstituted heteroaryl, a C-Csubstituted or unsubstituted alkyl or &#x2014;NR'R&#x2032;,

Heterodimers of glutamic acid

Compounds according to Formula I and Formula II are potent inhibitors of PSMA.  Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed. 

PSMA-targeted dendrimers

A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.

Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof

A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as: In the formula, X is selected from the group consisting of &#x2014;(CH)&#x2014;, &#x2014;(CH)&#x2014;O&#x2014;, &#x2014;(CH)&#x2014;N(R)&#x2014;, &#x2014;(CH)&#x2014;N(R)&#x2014;C(O)&#x2014; and &#x2014;O&#x2014;; Ris hydrogen or (C-C)alkyl; G is &#x2014;(CH(R))&#x2014;R&#x2014;, or &#x2014;(CH)&#x2014;C(O)&#x2014;R; G' is &#x2014;(CH(R))&#x2014;R&#x2014;, or &#x2014;(CH)&#x2014;C(O)&#x2014;R; Ris &#x2014;H, &#x2014;OH, NRR, or &#x2014;COH; Ris &#x2014;H, &#x2014;COOH, or substituted or unsubstituted &#x2014;COO(C-C)alkyl; Rand Rare each independently H, substituted or unsubstituted (C-C)alkyl, or substituted or unsubstituted carboxy(C-C)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX

Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity:  Pharmaceutical compositions may include a complex of a radionuclide and a compound of Formula I or Formula II.

Radiolabeled prostate specific membrane antigen inhibitors

A manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of readionuclide of a halogen in the presence of an oxidant under acidic condition, 

Process for production of heterodimers of glutamic acid

Growing community of inventors

Cambridge, MA, United States of America

Craig N Zimmerman